

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/165990 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) *A61K 45/06* (2006.01)
A61N 5/00 (2006.01) *A61K 103/30* (2006.01)
A61P 35/00 (2006.01) *A61K 103/00* (2006.01)
A61K 31/495 (2006.01)

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/IB2024/051083

(22) International Filing Date:

06 February 2024 (06.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/483,784 08 February 2023 (08.02.2023) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **MORAN, Stephen**; Novartis Pharmaceuticals
UK Limited, The WestWorks Building, White City, 195
Wood Lane, London Greater London W12 7FQ (GB). **AI-
MONE, Paola Daniela**; Novartis Pharma AG, Lichtstrasse
35, 4056 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse
35, 4056 Basel (CH).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR TREATING GLIOBLASTOMA

(57) Abstract: The present disclosure is directed to methods of treating glioblastoma in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a radiopharmaceutical compound with GRPR antagonist moiety, preferably [¹⁷⁷Lu]Lu-NeoB, in combination with radiotherapy, and optionally, with a therapeutically effective amount of an alkylating agent, preferably temozolomide.

WO 2024/165990 A1